Contingency Attorney Fees for Actos Cases

Financial compensation has been obtained for former users of the diabetes drug Actos diagnosed with bladder cancer, as the drug maker failed to properly research the potential side effects of Actos or adequately warn about the risk of bladder cancer.

The Actos attorneys at Saiontz & Kirk, P.A. are reviewing additional cases.

All Actos cases were handled by our law firm under a contingency fee agreement, which means that there were no attorney fees paid unless a recovery or Actos settlement was obtained.

ACTOS CASES

Actos (pioglitazone) is a type 2 diabetes drug that was introduced by Takeda Pharmaceuticals in July 1999. The medication has become a blockbuster seller for the drug maker, generating more than $4 billion in annual sales in recent years.

Contact Our Lawyers About an ACTOS INJURY LAWSUIT

  • This field is for validation purposes and should be left unchanged.

Saiontz & Kirk, PA, Attorneys & Lawyers, Baltimore, MD

Studies found that there was an association between Actos and bladder cancer, with a higher rate of the bladder tumors appearing among users of the popular diabetes drug.

While Takeda Pharmaceuticals devoted substantial resources to defending the litigation and their multi-billion dollar a year product, most diabetes patients diagnosed with bladder cancer from Actos can not afford to pay an hourly rate for the quality representation they deserve.

Through contingency attorney fees, every person — regardless of race, religion, national origin, gender or age — was able to obtain the highest quality representation without payment of any money out of their pocket. Contingency fees evened the playing field and allow individuals to hire our Actos attorneys and obtain the highest quality representation, regardless of their financial situation.

The law firm of Saiontz & Kirk, P.A. has a reputation for success and can protect your legal rights. Through contingency Actos attorney fees, you are able to obtain the best representation at no additional cost.